03 Profile
Hansard to 9 November 2026 · 31,243 contributions indexed · 1,439 MPs & peers
All voices01 Voice · Sector leader · Respiratory (asthma/COPD)
Kaivan Khavandi
head of respiratory, immunology, and inflammation R&D at GSK
press citations on 1 topic since 17 Feb 2026 · last quoted 23 Sept 2026
02 Quoted on · 1 of 29 topics
Kaivan Khavandi: key facts
- Kind of voice
- Sector leader
- Role
- head of respiratory, immunology, and inflammation R&D at GSK
- Quoted on
- Respiratory (asthma/COPD)
- Tracked press citations
- 2
- Most recently quoted
- 23 Sept 2026
- First quoted
- 17 Feb 2026
04 The signal · where Kaivan Khavandi sits on respiratory (asthma/copd)
Ranked 18= of 100 voices quoted in the press on respiratory (asthma/copd), level with 32 others on 2 citations.
Ranked on press citations on this topic only, not across all topics. Joint positions share a rank.
- 1=Darush Attar-ZadehClinicianExecutive Chair, Primary Care Respiratory Society; Clinical Fellow Respiratory Pharmacist, North West London Integrated Care Board, Primary Care Respiratory Society (PCRS)7
- 1=
Dr Andy WhittamoreClinicianClinical Lead (and practising GP), Asthma + Lung UK7 - 3
Alvar Agusti, MD, PhDAcademicProfessor of Medicine; Chair, GOLD Board of Directors, University of Barcelona / Hospital Clínic de Barcelona5 - 18=Dr Abhishek ShankarAcademicauthor of a perspective on lung cancer screening published by the IARC2
- 18=Dr. Meilan HanAcademicchief of the division of pulmonary and critical care at the University of Michigan Health and one of the investigators of the study2
- 18=Kaivan KhavandiSector leaderhead of respiratory, immunology, and inflammation R&D at GSK2
- 18=Dr Charlotte RandallClinicianConsultant forensic pathologist2
- 18=Dr Divya KathikeyanAcademicgeneral practitioner at TelDoc2
Showing the leaders and the ranks around 18=, of 100 voices · See every voice on the topic →
05 On the record · press
What Kaivan Khavandi has said
- es.tradingview.com1
- pharmaphorum.com1
Where Kaivan Khavandi has been quoted
- 01GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Carees.tradingview.com · 23 Sept 2026
- 02EU approval for new asthma drug Exdensur lifts GSKpharmaphorum.com · 17 Feb 2026
Verbatim
“GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches”
“redefine care for the millions of patients living with these persistent and burdensome conditions, supporting them in achieving their treatment goals with just two doses a year.”
Related media coverage
Recent UK press coverage of their topics, not necessarily citing them directly.
- Positive First ILD Pulmonary Rehabilitation programme for patients in the Omagh, Strabane and Fermanagh areaWestern Health & Social Care Trust
- Americans Are Open to Lung Cancer Screening, but Awareness and Education Have Not Caught UpIpsos
- Hospital trust admits mother’s death from missed pulmonary embolism was avoidable as family receives settlementLeigh Day
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. This profile was last updated on 5 Oct 2026. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.